RiverVest Venture Partners

Investing in Life Science Innovation

 
  • Home
  • About Us
  • Team
  • Portfolio
  • Case Studies
  • News
    • All News
    • RiverVest News
    • Newsletters
  • Contact Us

RiverVest News

RiverVest Venture Partners’ Otonomy Completes $100 Million Initial Public Offering

ST. LOUIS and SAN DIEGO (Aug. 13, 2014) – Otonomy, Inc., a RiverVest Fund II portfolio company that develops drug therapies for the inner and middle ear, announced today its $100 million initial public offering.

Candid Advice For Cash-Strapped Startups From A Biotech Venture Capitalist

By Josh Baxt, BioSpace.com Exclusive Story July 21, 2014 In a sense, Niall O’Donnell, Ph.D., and his colleagues at RiverVest Venture Partners run a biomedical adoption agency. They track down innovative discoveries, help raise them for a while and then find a good home, either at a pharmaceutical company or through public markets. For cash-strapped […]

15 Agents of Change in Medtech: No. 7: RiverVest Venture Partners

Medical Device and Diagnostic Industry May 28, 2014 Jamie Hartford  No. 7: RiverVest Venture Partners Passion or the desire to make a difference alone cannot bring about radical changes in the world of medtech. Money and the right guidance are equally crucial. That’s where venture capitalist firms—especially RiverVest Venture Partners—come in.  Read More

RiverVest Venture Partners’ portfolio company Lumena is Sold to Shire for $260 million; Represents Sixth Exit from RiverVest Venture Fund II

ST. LOUIS and SAN DIEGO (May 12, 2014) – RiverVest Venture Partners today announced portfolio company Lumena Pharmaceuticals has been sold to Dublin-based Shire Plc., in a transaction with an upfront payment of  $260 million in cash, plus a payment for net cash at closing, and near-term contingent milestone payments related to ongoing clinical trials.

RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner

ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner.

“The Frank Drebin Approach to Healthcare”

“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014.  Read more

RiverVest is investor in ZS Pharma’s $55 million financing

St. Louis Business Journal March 7, 2014 Brian Feldt, Reporter Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round. ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday.

RiverVest Venture Partners’ Bradley T. Keller Presents New Treatment for Cholestatic Liver Diseases at The Liver Meeting

ST. LOUIS and WASHINGTON, D.C. (Nov. 5, 2013) –RiverVest Venture Partners’ Bradley T. Keller presents research today on a potential new treatment for cholestatic liver diseases at The Liver Meeting in Washington, D.C. 

RiverVest sells portfolio company to Abbott Labs for $310 million

July 15, 2013 ST. LOUIS (St. Louis Business Journal) — Abbott Laboratories is acquiring IDEV Technologies, a RiverVest Venture Partners medical device portfolio company, for $310 million…  Read more.

RiverVest Venture Partners’ Medical Device Portfolio Company Sold to Abbott Laboratories for $310 million

ST. LOUIS, MO (July 15, 2013) – RiverVest Venture Partners announced today that Abbott Laboratories is acquiring RiverVest medical device portfolio company IDEV Technologies for $310 million.

Podcast: What Works When It Comes Time To Pitch

Cleveland, OH (July 9, 2013) –  In 2012, 108 Northeast Ohio companies raised $212 million in equity capital from angel and venture capitalists to grow their businesses. Still, the process of raising capital is a struggle for many, if not most, entrepreneurs. Imagine convincing potential investors—especially ones you don’t know—to put money into your company […]

RiverVest Venture Partners Names Pharmaceutical Veteran Bradley Keller as Entrepreneur-in-Residence

ST. LOUIS (May 13, 2013) – RiverVest Venture Partners announced today that Bradley Keller, Ph.D. has joined the life sciences venture capital firm as an Entrepreneur-in-Residence.

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

RiverVest Venture Partners

St. Louis Office
101 S. Hanley Road, Suite 1850
St. Louis, MO 63105
Phone: 314.726.6700
Fax: 314.726.6715
info@rivervest.com

San Diego Office
12730 High Bluff Drive, Suite 160
San Diego, CA 92130
Fax: 314.726.6715
info@rivervest.com

Cleveland Office
11000 Cedar Avenue, Suite 100
Cleveland, OH 44106
Phone: 216.658.3982
Fax: 314.726.6715
info@rivervest.com

  • LinkedIn
  • Twitter

Newsletter Sign Up

Copyright © 2019 RiverVest · All Rights Reserved · Powered by NeuConcept